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Abstract
Background: Pemphigus vulgaris (PV) is a severe autoimmune blistering skin disorder that is
strongly associated with major histocompatibility complex class II alleles DRB1*0402 and
DQB1*0503. The target antigen of PV, desmoglein 3 (Dsg3), is crucial for initiating T-cell response
in early disease. Although a number of T-cell specificities within Dsg3 have been reported, the
number is limited and the role of T-cells in the pathogenesis of PV remains poorly understood. We
report here a structure-based model for the prediction of peptide binding to DRB1*0402 and
DQB1*0503. The scoring functions were rigorously trained, tested and validated using
experimentally verified peptide sequences.
Results: High predictivity is obtained for both DRB1*0402 (r2 = 0.90, s = 1.20 kJ/mol, q2 = 0.82,
spress = 1.61 kJ/mol) and DQB1*0503 (r2 = 0.95, s = 1.20 kJ/mol, q2 = 0.75, spress = 2.15 kJ/mol)
models, compared to experimental data. We investigated the binding patterns of Dsg3 peptides and
illustrate the existence of multiple immunodominant epitopes that may be responsible for both
disease initiation and propagation in PV. Further analysis reveals that DRB1*0402 and DQB1*0503
may share similar specificities by binding peptides at different binding registers, thus providing a
molecular mechanism for the dual HLA association observed in PV.
Conclusion:  Collectively, the results of this study provide interesting new insights into the
pathology of PV. This is the first report illustrating high-level of cross-reactivity between both PV-
implicated alleles, DRB1*0402 and DQB1*0503, as well as the existence of a potentially large
number of T-cell epitopes throughout the entire Dsg3 extracellular domain (ECD) and
transmembrane region. Our results reveal that DR4 and DR6 PV may initiate in the ECD and
transmembrane region respectively, with implications for immunotherapeutic strategies for the
treatment of this autoimmune disease.
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Background
Pemphigus vulgaris (PV) is a severe autoimmune blister-
ing skin disorder due to loss of integrity of normal inter-
cellular attachments within the epidermis and mucosal
epithelium. Strong association of PV to the major histo-
compatibility complex (MHC) class II alleles DRB1*0402
and DQB1*0503 have been reported in the literature [1-
6] with over 95% of PV patients possessing one or both of
these alleles [7,8]. The molecular basis and immunologi-
cal consequences of this dual HLA association has thus far
not been elucidated. The target antigen of PV, desmoglein
(Dsg) 3, is a 130-kDa transmembrane glycoprotein that
belongs to the cadherin superfamily of cell adhesion mol-
ecules [9]. In the early stage of disease, patients demon-
strate autoimmunity only to Dsg3 and develop mucosal
blisters; while at the later stage, patients exhibit non-cross-
reactive immunity to both Dsg3 and Dsg1 [10]. Despite
several reports of T-cell specificities within Dsg3 [11-16],
the number is limited and the role of T-cells in the patho-
genesis of PV remains poorly understood.
Bioinformatic tools are now commonly used in facilitat-
ing T-cell epitope discovery [17-19]. Computational
methods for predicting MHC-binding peptides include
procedures based on sequence motifs [13,16], quantita-
tive matrices [20-22], decision trees [23,24], artificial neu-
ral networks [25,26], hidden Markov models [27] and
support vector machines [28-30]. However, despite recent
advances in sequence-based predictive techniques, effec-
tive models for DRB1*0402 and DQB1*0503 have been
lacking, mainly due to the paucity of sufficient peptides as
training data [31] as well as register-shifts (or positional
differences between the core nonameric peptide in the
binding groove) [31] and polymorphisms in the binding
registers (A.A. Sinha, unpublished results). To date, few
prediction techniques for MHC class II molecules have
been developed using three-dimensional models as the
dual issues of model quality and discrimination tech-
nique must be addressed [32].
Our strategy for prediction of T-cell epitopes involves the
three-dimensional modeling of peptide/MHC complexes
using a hybrid docking approach that integrates the
strengths of Monte Carlo simulations and homology
modeling [31,33,34]. In an earlier study, we have success-
fully discriminated disease-implicated from non-disease
implicated and protective alleles in PV based on structural
interaction rules [31]. A complementary scoring function
has now been developed for effective identification of
DRB1*0402 and DQB1*0503 epitopes. We investigated
the T-cell epitope repertoire of the entire Dsg3 glycopro-
tein and show the existence of multiple extracellular and
intracellular specificities within the Dsg3 self-antigen. Fur-
ther analysis reveal that DRB1*0402 and DQB1*0503
share similar specificities by binding peptides at different
core recognition regions. These data provide a molecular
rationale for the association of PV to two distinct HLA
molecules and impact our understanding of the mecha-
nism of HLA mediated control of disease.
Results and Discussion
DRB1*0402 predictive model
The DRB1*0402 model shows excellent correlation with
experimental binding affinities (r2 = 0.90, s = 1.20 kJ/mol,
q2 = 0.82, spress = 1.61 kJ/mol). The accuracy of the predic-
tion model was further evaluated using (i) peptides with
experimental IC50 values obtained from biochemical stud-
ies and (ii) Dsg3 peptides with T-cell proliferation values
obtained from functional studies.
Three threshold binding energy values (Table 1) that
define levels of specificities suitable for practical applica-
tions [34] were used to evaluate the accuracy of the
DRB1*0402 prediction model on the biochemical dataset
(Test set 1) – LMH (low-, medium-, high-affinity binders;
AROC = 0.93); MH (medium- and high-affinity binders;
AROC = 0.86) and H (high-affinity binders only; AROC =
0.81). The results indicate that, overall, our DRB1*0402
peptide-binding models are highly accurate (AROC = 0.93).
SP = 0.80 offers high-sensitivity predictions, whereas SP =
0.95 results in very few false positives but fewer true posi-
tives. The prediction results for our model were consistent
with expected binding patterns of DRB1*0402 peptides
and provided a sensitivity of 70% (SP = 0.95) for
DRB1*0402-binding peptides.
Next, the predictive performance of the DRB1*0402
model was tested on the functional dataset of 25 peptides
(Test set 2) with experimental T-cell proliferation values/
responses using the decision thresholds defined above. All
experimental positives (Table 2) are predicted with bind-
ing energy values of -26.64 kJ/mol or less (high-affinity
binders; SE = 0.65, SP = 0.80). Our simulation results
indicate that DRB1*0402 can bind Dsg3 96–112 at
threshold -26.64 kJ/mol (SE = 0.65, SP = 0.80) in contrast
to previous qualitative study results [31], albeit at a bind-
ing energy (-27.09 kJ/mol) close to the threshold. Dsg3
512–526 (ranked #10), Dsg3 78–93 (ranked #12) and
Dsg3 96–110 (ranked #19) are predicted binders (SE =
0.65, SP = 0.80) that did not stimulate T-cell responses in
the relevant experiments [11,13,16]. Noteworthy, pep-
tides Dsg3 78–93 [13] and Dsg3 96–110 [16] are fully
contained within Dsg3 78–94 (ranked #11) and Dsg3 96–
112 (ranked #22), both of which are experimental true
positives identified in an independent study [11]. For
Dsg3 78–93, the preferred binding register identified by
our models is 79–87, which is shows a 5-residue shift in
the binding register from the preferred core of 82–90 for
Dsg3 78–94. There is no change in the binding register
observed for Dsg3 96–110 and Dsg3 96–112. It is possibleBMC Bioinformatics 2006, 7(Suppl 5):S7
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that variability in the binding register (#12) or flanking
peptide residues (#19) lead to a change in T-cell stimula-
tion.
DQB1*0503 predictive model
The DQB1*0503 prediction model correlate well with
experimental data (r2  = 0.95, s  = 1.20 kJ/mol). The
DQB1*0503 model outperforms the prediction models
done by Rognan et al. (1999) on training datasets of 5
HLA-A*0204 (r2 = 0.85, spress = 2.40 kJ/mol) and 37 H2-Kk
(r2 = 0.78, spress = 3.16 kJ/mol) peptide sequences and is
consistent with our DRB1*0402 prediction model (r2 =
0.90, s = 1.20 kJ/mol, q2 = 0.82, spress = 1.61 kJ/mol) which
is trained using the same number of data points. The
cross-validation coefficient q2 and the standard error of
prediction spress are stable, with q2 = 0.75 and spress = 2.15 kJ/
mol. This iterative regression procedure validates the
internal consistency of the scoring function in the current
model, rendering it suitable for predictions on the test
dataset obtained from functional studies.
The accuracy of the DQB1*0503 prediction model was
assessed on a dataset of 6 (5 stimulatory and 1 non-stim-
ulatory peptides) Dsg3 peptides with known T-cell prolif-
eration values (Table 3). All DQB1*0503-specific Dsg3
stimulatory peptides can be effectively discriminated from
the background at the prediction threshold -26.64 kJ/mol.
Disease progression in PV
A variety of studies have demonstrated that a limited set
of epitopes may be present in early disease, and intra-
molecular epitope spreading may occur during disease
transition at the B-cell level [10]. Our data support the
existence of multiple immunodominant T-cell epitopes
that may be responsible for both disease initiation and
propagation (Figure 1 and Figure 2). These findings are in
line with T-cell proliferation data obtained from DR4 and
DR6 PV patients [11,13,15,16,31]. Our analysis showed
that the potential Dsg3 T-cell epitope repertoire is well
distributed throughout all five extracellular domains
(ECDs) (ECD1: Dsg3 50–158; ECD2: Dsg3 159–268;
ECD3: Dsg3 269–383; ECD4: Dsg3 386–499; ECD5:
Dsg3 500–615) [35]. A large number of DQB1*0503-spe-
cific Dsg3 peptides were predicted to exist within the
transmembrane region (Dsg3 616–640; Figure 2). Note-
worthy, 13 of these peptides were found among the top 20
predictions (Table 4), suggesting that disease initiation
may begin at the transmembrane region for DR6 PV
patients. Such an initiation step would not be unique to
PV as other studies have revealed disease initiation at the
transmembrane region [36,37]. For DRB1*0402, 90%
(18/20) of the top 20 predictions were predicted to exist
within the ECDs, suggesting that disease initiation in DR4
and DR6 PV patients may be different. Although two
DRB1*0402-specific intracellular peptides (Dsg3 762–
786, Dsg3 786–800) have been reported [13,16], and
were correctly detected by our model (SP = 0.80, SE =
0.65), relatively few intracellular peptides from the
region, Dsg3 641–999, are predicted by our methods. It
remains to be determined what proportion of the pre-
dicted epitopes are actually generated via antigen process-
ing events in vivo, or remain subdominant or "cryptic",
such that they are not available for recognition during the
initial immune response. It is likely that immune
responses develop against secondary epitopes at later
stages of disease progression, as a result of intramolecular
epitope spreading, and it will be important to delineate
the cascade of disease relevant epitopes in temporal
sequence in future work.
DRB1*0402 and DQB1*0503 cross reactivity
An in-depth analysis was performed to investigate the
extent of overlap in the Dsg3 peptide-binding repertoires
of DRB1*0402 and DQB1*0503. A panel of 936 15mer
Dsg3 sequences were generated using an overlapping slid-
ing window of size 15 across the entire Dsg3 glycoprotein
and modeled into the binding grooves of both
Table 1: Prediction accuracy of the DRB1*0402 peptide-binding model.
Specificity (SP) Level Group Sensitivity (SE) Binding Energy Threshold (kJ/mol)
SP = 0.80 LMH 0.78 -25.55
MH 0.81 -25.79
H 0.65 -26.64
SP = 0.90 LMH 0.75 -25.79
MH 0.52 -26.94
H 0.30 -28.83
SP = 0.95 LMH 0.70 -26.94
MH 0.42 -27.72
H 0.25 -30.57
Sensitivity (SE) values and binding energy thresholds for DRB1*0402 peptide-binding model at specificity (SP) levels 0.80, 0.90 and 0.95.BMC Bioinformatics 2006, 7(Suppl 5):S7
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DRB1*0402 and DQB1*0503 (explained in detail in Pep-
tide docking).
Both the DRB1*0402 and DQB1*0503 alleles are partic-
ularly efficient in binding Dsg3-derived peptides. Further-
more, a significant level of cross-reactivity was observed
between DRB1*0402 and DQB1*0503. Of the 936 over-
lapping 15mer peptides generated from the entire Dsg3
glycoprotein investigated in this study, 539 (57%) were
predicted high-affinity binders to both alleles at threshold
-26.64 kJ/mol. The computer simulation results are
shown in Figures 1 and 2. Noteworthy, three previously
defined immunoreactive segments of the Dsg3 extracellu-
lar domains (Dsg3 145–192, 240–303 and 570–614) [38]
were also predicted by our models at this specific thresh-
old. Among the known Dsg3 peptides (Tables 2 and 3),
only 2 (Dsg3 191–205 and 762–776) were predicted to
bind DRB1*0402 alone, consistent with our earlier quali-
tative results from structural studies alone [31]. 18 (Dsg3
78–94, 96–112, 161–177, 189–205, 190–204, 205–221,
206–220, 210–226, 250–266, 251–265, 342–356, 342–
358, 376–392, 380–396, 483–499, 786–800, 810–824,
963–977) were predicted to bind to both DRB1*0402 and
DQB1*0503. These observations are of particular interest
in that both DRB1*0402 and DQB1*0503 are strongly
linked to PV [39,40], indicating that common or overlap-
ping dominant epitopes may be responsible for inducing
disease in DR4 and DR6 patients respectively.
Table 3: Predicted binding affinities of Dsg3 peptide sequences to DQB1*0503.
Rank Peptide Sequence Predicted BE (kJ/mol) References
1 Dsg3 206–220 TPMFLLSRNTGEVRT -30.53 Wucherpfennig et al. (1995)
2 Dsg3 189–205 HLNSKIAFKIVSQEPAG -29.10 Veldman et al. (2004)
3 Dsg3 78–94 QATQKITYRISGVGIDQ -27.14 Veldman et al. (2004)
4 Dsg3 190–204 LNSKIAFKIVSQEPA -26.88 Wucherpfennig et al. (1995)
5 Dsg3 251–265 CECNIKVKDVNDNFP -26.65 Wucherpfennig et al. (1995)
6* Dsg3 762–786 QSGTMRTRHSTGGTNKDYADGAISM -22.42 Wucherpfennig et al. (1995)
Predicted binding affinities of Dsg3 peptide sequences to DQB1*0503. '*' indicates non-immunostimulatory in the relevant experiments.
Table 2: Predicted binding affinities of Dsg3 peptide sequences to DRB1*0402.
Rank Peptide Sequence Predicted BE (kJ/mol) References
1 Dsg3 342–358 SVKLSIAVKNKAEFHQS -31.46 Veldman et al. (2004)
2# Dsg3 342–356 SVKLSIAVKNKAEFH -30.88 Moesta et al. (2002)
3 Dsg3 205–221 GTPMFLLSRNTGEVRTL -30.44 Veldman et al. (2004)
4* # Dsg3 846–860 LDSLGPKFKKLAEIS -30.17 Moesta et al. (2002)
5 Dsg3 380–396 GIAFRPASKTFTVQKGI -29.97 Riechers et al. (1999)
6@ Dsg3 67–81 RNPIAKITSDYQATQ -29.94 Moesta et al. (2002)
7 Dsg3 786–800 MNFLDSYFSQKAFAC -29.78 Moesta et al. (2002)
8 Dsg3 190–204 LNSKIAFKIVSQEPA -29.74 Wucherpfennig et al. (1995)
9 Dsg3 189–205 HLNSKIAFKIVSQEPAG -29.24 Veldman et al. (2004)
10* Dsg3 512–526 SARTLNNRYTGPYTF -29.21 Wucherpfennig et al. (1995)
11 Dsg3 78–94 QATQKITYRISGVGIDQ -28.37 Veldman et al. (2004)
12* Dsg3 78–93 QATQKITYRISGVGID -28.30 Wucherpfennig et al. (1995)
13 Dsg3 191–205 NSKIAFKIVSQEPAG -28.16 Moesta et al. (2002)
14 Dsg3 206–220 TPMFLLSRNTGEVRT -28.02 Wucherpfennig et al. (1995)
15 Dsg3 210–226 LLSRNTGEVRTLTNSL -27.98 Veldman et al. (2004)
16 Dsg3 251–265 CECNIKVKDVNDNFP -27.88 Wucherpfennig et al. (1995)
17 Dsg3 250–266 QCECNIKVKDVNDNFPM -27.68 Veldman et al. (2004)
18 Dsg3 483–499 VRVPDFNDNCPTAVLEK -27.48 Veldman et al. (2004)
19* @ Dsg3 96–110 PFGIFVVDKNTGDIN -27.47 Moesta et al. (2002)
20 Dsg3 762–776 QSGTMRTRHSTGGTN -27.28 Wucherpfennig et al. (1995)
21 Dsg3 161–177 IFMGEIEENSASNSLVM -27.09 Hertl et al. (1998)
22 Dsg3 96–112 PFGIFVVDKNTGDINIT -27.09 Veldman et al. (2004)
23@ Dsg3 963–977 ERVICPISSVPGNLA -26.87 Moesta et al. (2002)
24* Dsg3 97–111 FGIFVVDKNTGDINI -26.58 Wucherpfennig et al. (1995)
25@ Dsg3 810–824 NDCLLIYDNEGADAT -24.00 Moesta et al. (2002)
Predicted binding affinities of Dsg3 peptide sequences to DRB1*0402. '#', '@', '*' indicate binding, non-binding and non-immunostimulatory in the 
relevant experiments respectively.BMC Bioinformatics 2006, 7(Suppl 5):S7
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Predicted DRB1*0402-specific T-cell epitope repertoire within Dsg3 Figure 1
Predicted DRB1*0402-specific T-cell epitope repertoire within Dsg3. Location of predicted DRB1*0402-specific T-
cell epitopes along the Dsg3 glycoprotein – extracellular domain (colored yellow; Dsg3 50–615), transmembrane region 
(colored green; Dsg3 616–640), and intracellular domain (colored pink; Dsg3 641–999). The red line indicates decision thresh-
old -26.64 kJ/mol for high-affinity binders (SP = 0.80, SE = 0.65).BMC Bioinformatics 2006, 7(Suppl 5):S7
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Predicted DQB1*0503-specific T-cell epitope repertoire within Dsg3 Figure 2
Predicted DQB1*0503-specific T-cell epitope repertoire within Dsg3. Location of predicted DQB1*0503-specific T-cell 
epitopes along the Dsg3 glycoprotein – extracellular domain (colored yellow; Dsg3 50–615), transmembrane region (colored 
green; Dsg3 616–640), and intracellular domain (colored pink; Dsg3 641–999). The red line indicates decision threshold -26.64 
kJ/mol for high-affinity binders (SP = 0.80, SE = 0.65).BMC Bioinformatics 2006, 7(Suppl 5):S7
Page 7 of 11
(page number not for citation purposes)
DRB1*0402 and DQB1*0503 peptide binding specificities
The basis for the high degree of cross-reactivities between
DRB1*0402 and DQB1*0503 was subjected to further
analysis. Our data support the existence of multiple bind-
ing registers within a candidate binding peptide that serve
as recognition sites for DRB1*0402 and DQB1*0503, an
observation previously noted for DQB1*0302 binding
peptides [34]. Of 936 Dsg3 sequences, 614 were predicted
high-affinity binders with 76% displaying 2 or more reg-
isters that can be docked into the binding groove of
DRB1*0402 (Figure 3). Similar results are obtained for
DQB1*0503, with 673 predicted high-affinity binders
and 57% exhibiting 2 or more binding registers (Figure 3).
DRB1*0402 and DQB1*0503 predicted consensus bind-
ing sequences number 539. A striking aspect of this anal-
ysis is that DRB1*0402 and DQB1*0503 were predicted
to bind a large portion of these peptides (354/539 or
66%) at different binding registers. Noteworthy, this dif-
ference was detected in 70% (7/10) of Dsg3 peptides
known to bind both DRB1*0402 and DQB1*0503 (Table
5). For example, the consensus binding peptide Dsg 205–
221 showed ΔG values less than the decision threshold -
26.64 kJ/mol, with the 211–219 and 212–220 registers
being the preferred binding modes for DRB1*0402 and
DQB1*0503 respectively. We propose that DRB1*0402
and DQB1*0503 share similar specificities by binding
peptides at different binding registers.
Conclusion
Although PV was first reported by Hippocrates in 400
B.C., few T-cell specificities within Dsg3 have been identi-
fied to date [11-16], and the role of MHC and T-cells in
the pathogenesis of PV still remains poorly understood.
Collectively, the results of this study provide interesting
new insights into the pathology of PV. This is the first
report of high-level of cross-reactivity between both PV-
implicated alleles, DRB1*0402 and DQB1*0503, as well
as the existence of a potentially large number of T-cell
epitopes throughout the entire Dsg3 ECD and transmem-
brane region. Our data strongly indicates that multiple
initial epitopes may be responsible for both disease initi-
ation and progression. In addition, our modelling results
revealed that DR4 and DR6 PV may initiate at different
regions of Dsg3. DR4 PV may initiate in the ECD while
DR6 PV may begin at the transmembrane region. It
remains to be determined what proportion of predicted
DRB1*0402 and DQB1*0503 binders are capable of
stimulating PV-implicated alleles and autoreactive T-cells.
If experimental analysis reveals limited sets of predicted
Dsg3 peptides capable of eliciting functional responses,
control over autoreactivity may rest at the T-cell level,
rather than the level of determinant selection by MHC
molecules. This will have a direct impact in the design of
immunotherapeutic strategies for the treatment of this
autoimmune disease.
Methods
MHC sequence data were obtained from IMGT-HLA data-
base [41]. To identify potential structural templates avail-
able in the Protein Data Bank (PDB) [42] for model
building, a sequence similarity search was performed
using PSI-BLAST [43] running on the servers at NCBI and
the highest quality templates (with the best resolution,
highest sequence similarity and minimal number of miss-
Table 4: Top 20 predicted Dsg3 peptide sequences binding to DQB1*0503 and DRB1*0402.
Rank DQB1*0503 DRB1*0402
Peptide Sequence Predicted B.E. (kJ/mol) Peptide Sequence Predicted B.E. (kJ/mol)
1 Dsg3 627–641 GLLLLLLAPLLLLTC -39.23 Dsg3 601–615 TTSPGTRYGRPHSGR -34.64
2 Dsg3 626–640 LGLLLLLLAPLLLLT -38.43 Dsg3 263–277 NFPMFRDSQYSARIE -33.86
3 Dsg3 624–638 LLLGLLLLLLAPLLL -37.87 Dsg3 844–858 SFLDSLGPKFKKLAE -33.46
4 Dsg3 629–643 LLLLLAPLLLLTCDC -37.82 Dsg3 264–278 FPMFRDSQYSARIEE -33.22
5 Dsg3 625–639 LLGLLLLLLAPLLLL -37.65 Dsg3 599–613 YPTTSPGTRYGRPHS -33.10
6 Dsg3 628–642 LLLLLLAPLLLLTCD -37.47 Dsg3 352–366 KAEFHQSVISRYRVQ -32.88
7 Dsg3 620–634 AIGLLLLGLLLLLLA -36.48 Dsg3 598–612 SYPTTSPGTRYGRPH -32.76
8 Dsg3 623–637 LLLLGLLLLLLAPLL -36.44 Dsg3 442–456 AEIKFVKNMNRDSTF- 3 2 . 6 0
9 Dsg3 618–632 PAAIGLLLLGLLLLL -36.36 Dsg3 440–454 KTAEIKFVKNMNRDS -32.56
10 Dsg3 293–307 LDEEYTDNWLAVYFF -36.28 Dsg3 439–453 SKTAEIKFVKNMNRD -32.36
11 Dsg3 622–636 GLLLLGLLLLLLAPL -36.23 Dsg3 52–66 VKFAKPCREGEDNSK- 3 2 . 1 3
12 Dsg3 619–633 AAIGLLLLGLLLLLL -36.20 Dsg3 186–200 EPNHLNSKIAFKIVS -32.10
13 Dsg3 294–308 DEEYTDNWLAVYFFT -36.15 Dsg3 354–368 EFHQSVISRYRVQST -32.10
14 Dsg3 621–635 IGLLLLGLLLLLLAP -35.67 Dsg3 247–261 LSTQCECNIKVKDVN- 3 2 . 0 8
15 Dsg3 297–311 YTDNWLAVYFFTSGN -35.28 Dsg3 262–276 DNFPMFRDSQYSARI -32.07
16 Dsg3 483–497 VRVPDFNDNCPTAVL -35.17 Dsg3 845–859 FLDSLGPKFKKLAEI -32.07
17 Dsg3 616–630 LGPAAIGLLLLGLLL -34.86 Dsg3 954–968 LLTQNVIVTERVICP -31.93
18 Dsg3 317–331 EIQTDPRTNEGILKV -34.75 Dsg3 351–365 NKAEFHQSVISRYRV -31.87
19 Dsg3 295–309 EEYTDNWLAVYFFTS -34.67 Dsg3 344–358 KLSIAVKNKAEFHQS -31.85
20 Dsg3 136–150 DVEKPLILTVKILDI -34.63 Dsg3 441–455 TAEIKFVKNMNRDST -31.72
The nonameric core peptide in the binding groove is shown in bold, underlined text.BMC Bioinformatics 2006, 7(Suppl 5):S7
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ing residues) were selected among the returned results.
The crystal structures of DRB1*0401 (PDB code 1D5Z)
and DQB1*0602 (PDB code 1UVQ) were selected as tem-
plates for DRB1*0402 (97.9% identity) and DQB1*0503
(93.0% identity) respectively.
Model building
The program MODELLER [44] was employed for compar-
ative modeling of both DRB1*0402 and DQB1*0503.
The models are constructed by optimally satisfying spatial
constraints obtained from the alignment of the template
structure with the target sequence and from the
CHARMM-22 force field [45]. The structures were relaxed
by conjugate gradient minimization, using the Internal
Coordinate Mechanics (ICM) 3.0 package [46].
Experimental binding data
Two sets of data are used in this study: (i) peptides with
experimental IC50 values from biochemical studies and
(ii) peptides with experimental T-cell proliferation values/
responses from functional studies.
Dataset I (Additional file 1: Table S1) comprises 59
DRB1*0402-specific peptides derived from biochemical
studies (20 high-affinity, 11 medium-affinity and 13 low-
affinity binders and 15 non-binders). Peptides are classi-
fied based on their experimental IC50 values (high-affinity
binders: IC50 ≤ 500 nM, medium-affinity binders: 500 nM
< IC50 ≤ 1500 nM, low-affinity binders: 1500 < IC50 ≤
5000 nM and non-binders: 5000 < IC50).
Dataset II (Additional file 2: Table S2) consists of 25
DRB1*0402-specific Dsg3 peptides and 14 DQB1*0503-
specific Dsg3 peptides with T-cell proliferation values/
responses [11-13].
Peptide docking
Overlapping 15-mer peptides are generated from the Dsg3
sequence. An overlapping sliding window of size nine is
applied to each 15-mer peptide to generate all combina-
tions of binding registers to be modeled into the binding
grooves of DRB1*0402 and DQB1*0503. Docking was
performed with the Empirical Conformational Energy
Program for Peptides 3 force field parameters (ECEPP/3)
[46] and MMFF partial charges [47] on a 4-CPU SGI Ori-
Predicted binding registers for Dsg3 peptides bound to DRB1*0402 and DQB1*0503 Figure 3
Predicted binding registers for Dsg3 peptides bound to DRB1*0402 and DQB1*0503. The frequency of Dsg3 peptides docked 
to DRB1*0402 (colored gray) and DQB1*0503 (colored white) is shown as a function of the number of predicted binding reg-
isters.BMC Bioinformatics 2006, 7(Suppl 5):S7
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gin 3200 workstation using an extension of the protocol
[33,34]: (i) pseudo-Brownian rigid body docking of pep-
tide fragments to the ends of the binding groove, (ii) cen-
tral loop closure by satisfaction of spatial constraints, (iii)
refinement of the backbone and side-chain atoms of the
core recognition residues and receptor contact regions
within 4.00Å radius [31,33] and (iv) extension of flanking
peptide residues by satisfaction of spatial constraints.
Empirical free energy functions
The scoring function presented in this study is based on
the free energy potential in ICM3.0 package [47]. The
binding free energy function is partitioned into three
terms [34] expressed by the equation:
ΔG = αΔGH + βΔGS + γΔGEL + C.   (1)
ΔGH is the hydrophobic energy computed as the product
of solvent accessible surface area (determined by rolling a
sphere of 1.40Å radius along the surface of the molecule)
by the surface tension. ΔGS refers to the entropic contribu-
tion from the protein side-chains computed from the
maximal burial entropies for each type of amino acid and
their relative accessibilities. ΔGEL denotes the electrostatic
term composed of coulombic interactions between recep-
tor and ligand and the desolvation of partial charges trans-
ferred from an aqueous medium to a protein core
environment, and is determined by the numeric solution
of the Poisson equation using an implementation of the
boundary element algorithm [48-50]. The constant term
C accounts for entropy change in the system due to the
decrease of free molecular concentration and the loss of
rotational/translational degrees of freedom upon binding
[51].
Training, testing and validation
Two computational models are trained in this study – one
model for the prediction of peptide binding to
DRB1*0402 and the other for DQB1*0503.
DRB1*0402-specific peptide data derived from biochem-
ical studies with experimental IC50 values was divided into
training and test sets. The training set comprised 8 (5
binding and 3 non-binding) Dsg3 sequences with experi-
mentally determined binding registers (from Dataset I).
Two external sets of test data were used: (i) Test set 1: 51
peptides with experimental IC50 values (20 high-affinity
binders, 11 medium affinity binders, 9 low affinity bind-
ers and 11 non-binders) from biochemical studies, and
(ii) Test set 2: all DRB1*0402-specific Dsg3 peptides from
Dataset II, with known T-cell proliferation values.
DQB1*0503 prediction model was trained using Dsg3
peptide data from functional studies in the absence of rel-
evant biochemical data. The training set comprised 8 (5
stimulatory and 3 non-stimulatory) sequences from Data-
set II. For each peptide sequence, T-cell proliferation value
[13] is mapped to a theoretical IC50 value in accordance
with expected binding patterns of Dsg3 binding peptides
(Sinha  et al., personal communications). The perform-
ance of the prediction model was subsequently evaluated
on an external set of 6 peptides with known T-cell prolif-
eration values.
Coefficients (α, β, γ) and the constant term C in Equation
1 were derived using standard least-square multivariate
regression analyses of the training set, followed by leave-
one-out analysis to assess to quality of the scoring func-
tion [52]. For each model, the entire procedure is repeated
Table 5: Preferred binding registers of experimentally determined Dsg3 peptides for PV implicated alleles.
Peptide Allele Sequence Peptide Allele Sequence
Dsg3 78–94 DRB1*0402 QATQKITYRISGVGIDQ Dsg3 250–266 DRB1*0402 QCECNIKVKDVNDNFPM
DQB1*0503 QATQKITYRISGVGIDQ DQB1*0503 QCECNIKVKDVNDNFPM
Dsg3 96–112 DRB1*0402 PFGIFVVDKNTGDINIT Dsg3 251–265 DRB1*0402 CECNIKVKDVNDNFP
DQB1*0503 PFGIFVVDKNTGDINIT DQB1*0503 CECNIKVKDVNDNFP
Dsg3 161–177 DRB1*0402 IFMGEIEENSASNSLVM Dsg3 342–356 DRB1*0402 SVKLSIAVKNKAEFH
Dsg3 189–205 DRB1*0402 HLNSKIAFKIVSQEPAG Dsg3 342–358 DRB1*0402 SVKLSIAVKNKAEFHQS
DQB1*0503 HLNSKIAFKIVSQEPAG DQB1*0503 SVKLSIAVKNKAEFHQS
Dsg3 190–204 DRB1*0402 LNSKIAFKIVSQEPA Dsg3 376–392 DQB1*0503 NVREGIAFRPASKTFTV
DQB1*0503 LNSKIAFKIVSQEPA Dsg3 380–396 DRB1*0402 GIAFRPASKTFTVQKGI
Dsg3 191–205 DRB1*0402 NSKIAFKIVSQEPAG Dsg3 483–499 DRB1*0402 VRVPDFNDNCPTAVLEK
Dsg3 205–221 DRB1*0402 GTPMFLLSRNTGEVRTL Dsg3 762–776 DRB1*0402 QSGTMRTRHSTGGTN
DQB1*0503 GTPMFLLSRNTGEVRTL Dsg3 786–800 DRB1*0402 MNFLDSYFSQKAFAC
Dsg3 206–220 DRB1*0402 TPMFLLSRNTGEVRT Dsg3 810–824 DRB1*0402 NDCLLIYDNEGADAT
DQB1*0503 TPMFLLSRNTGEVRT Dsg3 963–977 DRB1*0402 ERVICPISSVPGNLA
Dsg3 210–226 DRB1*0402 LLSRNTGEVRTLTNSL
Preferred binding registers of experimentally determined Dsg3 peptides for PV implicated alleles. Best fitting registers with lowest predicted binding 
energies are in bold, underlined text.BMC Bioinformatics 2006, 7(Suppl 5):S7
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8 times to reduce noises in all computations, the results
averaged and the observed error rate is used to estimate
the expected error rate upon generalization to new data.
The optimal scoring function selected from each cross-val-
idation analysis was further assessed using sensitivity
(SE), specificity (SP) and receiver operating characteristic
(ROC) analysis [34]. SE = TP/(TP+FN) and SP = TN/
(TN+FP), indicate percentages of correctly predicted bind-
ers and non-binders, respectively. TP (true positives) rep-
resents experimental binders with at least one predicted
binding register and TN (true negatives) for experimental
non-binders with no predicted binding register. FN (false
negatives) denotes experimental binders predicted as
non-binders and FP (false positives) represents experi-
mental non-binders predicted as binders. The accuracy of
our predictions was assessed by ROC analysis where the
ROC curve is generated by plotting SE as a function of (1-
SP) for various classification thresholds. The area under
the ROC curve (AROC) provides a measure of overall pre-
diction accuracy, AROC <70% for poor, AROC>80% for
good and AROC>90% for excellent predictions [34]. In this
study, we assessed SE for three values of SP (80%, 90%
and 95%) that are considered useful in practice. All regres-
sion and validation results, including correlation coeffi-
cient (r2), standard deviation (s), cross-validation
coefficient (q2), standard error of prediction (spress), SE,
SP, AROC, coefficients and constant terms in the scoring
function, are recorded.
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